Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБУ «Поликлиника №1» УД Президента РФ, Москва, Россия; 2 Клиника головной боли и вегетативных расстройств им. акад. Александра Вейна, Москва, Россия; 3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия garmanova_aa@bk.ru
Список исп. литературыСкрыть список 1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. 2. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-21. 3. Steiner TJ, Stovner LJ, Jensen R et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. 4. Ayzenberg I, Katsarava Z, Sborowski A et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32(5):373-81. 5. Sacco S, Bendtsen L, Ashina M, Reuter U et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1): 6. Филатова Е.Г., Осипова В.В., Табеева Г.Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4-14. Filatova E.G., Osipova V.V., Tabeeva G.R. et al. Diagnosis and treatment of migraine: recommendations of Russian experts. Neurology, neuropsychiatry, psychosomatics. 2020;12(4):4-14 (in Russian). 7. Амелин А.В., Соколов А.Ю., Ваганова Ю.С. Пятилетний опыт применения нового класса препаратов для таргетной профилактической терапии мигрени. Российский неврологический журнал. 2021;26(3):4-14. Amelin A.V., Sokolov A.Yu., Vaganova Yu.S. Five-year experience in the use of a new class of drugs for targeted preventive therapy of migraine. Russian Neurological Journal. 2021;26(3):4-14 (in Russian). 8. Zhang Q, Shao A, Jiang Z et al. The exploration of mechanisms of comorbidity between migraine and depression. J Cell Mol Med. 2019;23(7):42505-4513. 9. Ashina S, Serrano D, Lipton RB et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13(8):615-24. 10. Peres MFP, Mercante JPP et al. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain. 2017;18(1):37. 11. Smitherman TA, Kolivas ED, Bailey JR. Panic disorder and migraine: comorbidity, mechanisms, and clinical implications. Headache. 2013;53(1):23-45. 12. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache. 2006;46(9):1327-33. 13. Jette N, Patten S, Williams J et al. Comorbidity of migraine and psychiatric disorders—a national population-based study. Headache. 2008;48(4):501-16. 14. Buse DC, Manack A, Serrano D et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-32. 15. Blumenfeld AM, Varon SF, Wilcox TK et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301-15. 16. Артеменко А.Р., Куренков А.Л., Антипова О.С. Диагностика и лечение хронической мигрени. М.: Горячая линия – Телеком, 2014. Artemenko A.R., Kurenkov A.L., Antipova O.S. Diagnostics and treatment of chronic migraine. Moscow: Goryachaya liniya – Telekom, 2014 (in Russian). 17. Frediani F, Villani V. Migraine and depression. Neurol Sci. 2007;28 (Suppl. 2):S161-5. 18. Сергеев А.В., Табеева Г.Р., Филатова Е.Г. и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. Sergeev A.V., Tabeeva G.R., Filatova E.G. et al. Application of a new biological pathogenetic therapy of migraine in clinical practice: consensus of experts of the Russian Society for the Study of Headache. Neurology, neuropsychiatry, psychosomatics. 2022;14(5):109-16 (in Russian). 19. Ashina M, Goadsby PJ, Reuter U et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716-25. 20. De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, Sacco S, Ornello R. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci. 2021;42(8):3297-303. 21. Nsaka M, Scheffler A, Wurthmann S et al. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Brain Behav. 2022;12(7):e2662.